Why is Boston Scientific stock sliding today?

Boston Scientific (BSX) shares fell 3.6% to $43.42 in pre-market trading after reporting Q3 2026 earnings. Adjusted EPS of $0.73 missed estimates by $0.02, while revenue of $5.14B exceeded expectations. The company cut Q4 and full-year 2026 EPS guidance due to a cyberattack and other challenges, citing a 1%-3% expected decline in Q4 sales.

Original reporting
Published Oct 28, 2026, 11:22 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 11:28 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$BSX
Bearish
high confidence
Mentioned
$BSX
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$BSXBearishHigh
01

Why it matters

The earnings miss and guidance cut are likely to trigger short‑term selling pressure, especially given the recent cyber‑attack disruption.

02

Market read

The earnings surprise and guidance downgrade are primary catalysts for a near‑term price decline.

03

What to watch

Potential upside from upcoming product launches or cost‑saving initiatives not reflected in the guidance.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Boston Scientific's Q3 results were released before the bell, highlighting a modest revenue beat but a miss on EPS and a significant guidance reduction.

Company-level read

Ticker impact

$BSXBearishHigh confidence
Context

Boston Scientific reported Q3 2026 earnings miss and cut full-year guidance, causing a 3.6% pre‑market slide.

Expected impact

likely further decline as investors price in weaker earnings and guidance

Evidence & confidence

Adjusted EPS fell short of consensus and full‑year EPS guidance was trimmed, a material catalyst for short‑term sell pressure.

Market effects

Medical device sector may face broader scrutiny as guidance cuts signal slower demand.

U.S. healthcare stocks could see modest weakness in early trade.

Limited; impact confined mainly to U.S. equities.

Counterpoint

If the cyber‑attack impact eases faster than expected, the stock could rebound on a valuation discount.

Key entities

  • Boston Scientific

    Medical device maker reporting Q3 2026 earnings.

Related articles

$BSXMed

BSX's Weak Solvency and Cash Conversion Raise Financing Risk

Boston Scientific (BSX) reported $609M in cash, $11.95B in debt, and Q3 free cash flow of $867M. Adjusted gross margin fell 300bps YoY to 68% due to a cybersecurity incident. BSX lowered its full-year free cash flow outlook to $3.6B. The company faces margin pressure, pricing pressure in China, and acquisition-related obligations. BSX shares have declined 56% YoY, trading at a 12-month forward P/S of 3.00X. Analysts have reduced BSX's 2026 earnings estimate by 2.2% over the past 30 days.

$PHGMed

New Study Shows How Hybrid Imaging Can Guide Coronary Treatment Decisions

Conavi Medical (TSXV: CNVI, OTCQB: CNVIF) received FDA 510(k) clearance for its hybrid imaging system, combining IVUS and OCT. The company reported first U.S. commercial placement, early clinical benefits, and extended credit facilities. Peer-reviewed research supports hybrid imaging for coronary treatment decisions. Conavi aims to expand physician adoption and hospital placements.